Changes in cardiometabolic factors such as body mass index (BMI), glucose levels, and blood pressure (BP) may signify dementia risk up to 14 years pre-diagnosis, with management of these risk factors potentially preventing dementia, according to a French population-based study presented at the Alzheimer’s Association International Conference (AAIC 2018).
The first clinical practice guidelines (CPGs) for evaluating Alzheimer’s disease and Related Dementias (ADRD) in both the primary and specialty care settings were revealed at the recent Alzheimer’s Association International Conference (AAIC 2018) in Chicago, Illinois, US.
A new study reinforces the gut-brain connection in Alzheimer’s disease (AD), untangling the complex interplay between gut and brain health that could potentially lead to new therapies targeted at manipulating the gut microbiome to treat AD.
Incorporating virtual reality (VR) modules into the ‘Bringing Art to Life’ (BATL) service learning programme provided participants with a greater understanding of people with Alzheimer’s disease (AD) and other dementias (PWDs), according to a presentation at the Alzheimer’s Association International Conference (AAIC 2018).
Fewer children, older age at menarche, and a higher number of miscarriages are among factors that may raise a woman’s risk of dementia, according to a study presented at the recent Alzheimer’s Association International Conference (AAIC 2018).
The novel oral BACE* inhibitor elenbecestat showed an acceptable safety profile and was generally well tolerated in patients with mild cognitive impairment (MCI)-to-moderate Alzheimer’s disease (AD), with additional benefit of reducing amyloid load in the brain, a new study finds.
There is no evidence that hormone replacement therapy (HRT) may affect cognitive ability, especially when it is initiated early on during menopausal transition, according to studies presented at AAIC 2018, suggesting a need to rethink the long-held belief that HRT may negatively affect cognition.
The synthetic cannabinoid nabilone significantly improves noncognitive symptoms, in particular agitation, in people with moderate-to-severe Alzheimer's disease (AD), suggests a small randomized controlled trial.
Intensive systolic blood pressure (SBP) lowering to <120 mm Hg significantly reduced the risk of mental decline that can lead to Alzheimer’s disease, reveals the SPRINT* MIND study presented at the Alzheimer's Association International Conference (AAIC) 2018.